Atomoxetine ( DrugBank: Atomoxetine )

---

4 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	5
8	Huntington disease	1
13	Multiple sclerosis/Neuromyelitis optica	1
17	Multiple system atrophy	1

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02879136 (ClinicalTrials.gov)	December 2016	23/6/2016	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study	Parkinson's Disease, Idiopathic	Drug: Methylphenidate;Other: Physical Therapy;Drug: Atomoxetine	Hubert Fernandez	NULL	Recruiting	18 Years	90 Years	All	42	Early Phase 1	United States
2	NCT03651856 (ClinicalTrials.gov)	January 2013	2/7/2018	Atomoxetine for Freezing of Gait in Parkinson's Disease	A Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's Disease	Parkinson's Disease;Freezing of Gait	Drug: ATM FOG in PD	Medical University of South Carolina	NULL	Completed	18 Years	80 Years	All	10	Phase 3	United States
3	NCT01738191 (ClinicalTrials.gov)	November 2012	28/11/2012	Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)	Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)	Parkinson's Disease;Cognitive Impairment	Drug: Atomoxetine;Drug: Placebo	Medical University of South Carolina	Michael J. Fox Foundation for Parkinson's Research	Completed	35 Years	75 Years	All	30	Phase 2	United States
4	NCT00286949 (ClinicalTrials.gov)	January 6, 2005	3/2/2006	Treatment of Executive Dysfunction in Parkinson's Disease	Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study	Parkinson's Disease	Drug: Atomoxetine	Johns Hopkins University	Eli Lilly and Company	Completed	21 Years	65 Years	All	12	N/A	United States
5	NCT00304161 (ClinicalTrials.gov)	July 2004	15/3/2006	Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease	Depression Diagnosis and Treatment in Parkinson Disease	Depressive Disorder;Parkinson Disease	Drug: Atomoxetine;Drug: Placebo	University of Pennsylvania	National Institute of Mental Health (NIMH)	Completed	30 Years	79 Years	All	55	Phase 4	United States

Back to top

8. Huntington disease

---

Clinical trials : 242 /  Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00368849 (ClinicalTrials.gov)	November 2005	24/8/2006	Atomoxetine and Huntington's Disease	Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study	Huntington Disease;Chorea	Drug: atomoxetine;Drug: Matching Placebo	University of Iowa	Eli Lilly and Company	Completed	18 Years	65 Years	All	20	Phase 2	United States

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03091400 (ClinicalTrials.gov)	March 16, 2017	16/3/2017	Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)	Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis	Memory Disorders;Multiple Sclerosis	Drug: Atomoxetine;Drug: Placebo	Icahn School of Medicine at Mount Sinai	NULL	Completed	21 Years	60 Years	All	11	Phase 2	United States

17. Multiple system atrophy

---

Clinical trials : 119 /  Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04782830 (ClinicalTrials.gov)	February 5, 2021	1/3/2021	Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms	Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms	Orthostatic; Hypotension, Neurogenic;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy; Hypotension, Parkinsonism	Device: Accelerometer;Drug: placebo pill;Drug: Midodrine or atomoxetine pill	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	29	N/A	United States

Back to top